Ocugen (OCGN) stock already rose by 68% since the company's COVID-19 vaccine co-development partner, Bharat Biotech, shared positive results of the Phase 3 study of COVAXIN.
On Wednesday, the company said that COVAXIN demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78% with efficacy against severe COVID-19 disease alone of 100%. It can significantly limit the spread of asymptomatic COVID-19 infections based on efficacy shown to date.
The company also said that given the remarkable safety and efficacy which demonstrated by COVAXIN vaccine, it plans to consider clinical development in special populations such as children.
This is a big news for investors who own the company's stock. Currently, we have learned in known press releases that the company could throw their COVID-19 vaccine to countries sucn as United States, India and Mexico after approved by regulatory authorities. India is a populous country and it has high demand for COVID-19 vaccine as well. In short, the stock is worth to add your watch list.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.